EGFR and colorectal carcinoma: The Misale et al. study reports for the first time that a substantial fraction of CRC patients who exhibit an initial response to anti-EGFR therapies have, at the time of disease progression, tumors with focal amplification or somatic mutations in KRAS which were not detectable prior to therapy initiation [108].